

# Longitudinal Analysis of Disease Progression Using Image and Laboratory Data for Covid-19 Patients

## Additional Material

Verena Bentele<sup>1,†</sup>, Francesca De Benetti<sup>1,†</sup>, Egon Burian<sup>2,3</sup>, Marcus Makowski<sup>2</sup>,  
Nassir Navab<sup>1,4</sup>, Rickmer Braren<sup>2</sup>, Thomas Wendler<sup>1</sup>

<sup>1</sup>Chair for Computer Aided Medical Procedures and Augmented Reality, TU Munich

<sup>2</sup>Department of Diagnostic and Interventional Radiology, TU Munich

<sup>3</sup>Department of Diagnostic and Interventional Neuroradiology, TU Munich

<sup>4</sup>Computer Aided Medical Procedures Lab, Laboratory for Computational Sensing+Robotics,  
Johns Hopkins University

† These authors contributed equally to this work.

francesca.de-benetti@tum.de

## 1 List of features

### 1.1 Demographic features

**Sex** categories: male [0], female [1]

**Age** in years

### 1.2 Clinical features

|  |   |
|--|---|
| <b>Hospital stay</b>                             | in days - Duration of the complete in-house hospital stay; sum of “Stationary stay” and “ICU stay”                                |
| <b>Stationary stay</b>                           | in days - Duration of the stationary in-house hospital stay   |
| <b>ICU stay</b>                                  | in days - Duration of the in-house intensive care unit (ICU) stay   |
| <b>Duration of intubation</b>                    | in days - Period during which the patient was intubated   |
| <b>Duration of invasive ventilation</b>          | in days - Period during which the patient was invasively ventilated through a tube or tracheostoma.                               |
| <b>Time: symptoms to hospital admission</b>      | in days   |
| <b>Time: symptoms to ICU admission</b>           | in days   |
| <b>Time: hospital admission to ICU admission</b> | in days   |
| <b>Outcome (30 days)</b>                         | categories: the patient passed away [1], the patient is hospitalized with extracorporeal membrane oxygenation (ECMO) therapy [2], |

|                                       |  |
|---------------------------------------|--|
|                                       | the patient is hospitalized with invasive ventilation support [3], the patient is hospitalized with non-invasive ventilation support [4], the patient is hospitalized without oxygen requirement [5], the patient was meanwhile moved to another health care facility [6], the patient was meanwhile discharged home [7] - Description of the patient's health care status 30 days after Covid-19 disease has been diagnosed |
| <b>Death</b>                          | categories: the patient did not die during the observed hospital stay [0], the patient died during the observed hospital stay [1]  |
| <b>SpO2</b>                           | in % - All measurements were performed at the time of hospital admission when the patients did not experience any additional ventilation; data imputation of 6%, missing values were replaced by cohort's (gender- and wave-specific) median   |
| <b>Use of invasive ventilation</b>    | categories: no [0], yes [1]  |
| <b>Use of ECMO</b>                    | categories: no [0], yes [1]; ECMO = extra-corporal membrane oxygenation  |
| <b>Use of proning</b>                 | categories: no [0], yes [1]  |
| <b>Use of tracheotomy</b>             | categories: no [0], yes [1]  |
| <b>Use of hemodialysis</b>            | categories: no [0], yes [1]  |
| <b>Use of ADVOS</b>                   | categories: no [0], yes [1]; ADVOS = advanced organ support  |
| <b>Use of catecholamine treatment</b> | categories: no [0], yes [1]  |
| <b>Use of dexamethasone treatment</b> | categories: no [0], yes [1]  |

### 1.3 Laboratory features

For each listed laboratory parameter we collected values at two times, namely  $\pm 1$  day to the corresponding lung CT scan at  $T_0$  (initial CT) and  $T_1$  (follow up CT). The  $\Delta$  of the values was computed by subtracting the initial value from the follow up value. If a value was not analyzed for a patient at the required time we applied data imputation and replaced the missing value by the cohort's (gender- and wave-specific) mean.

|                     |   |
|---------------------|---|
| <b>Hemoglobin</b>   | in g/dl for $T_0/ T_1/\Delta$ ; data imputation of 1%             |
| <b>Leukocytes</b>   | in G/l for $T_0/ T_1/\Delta$ ; data imputation of 1%              |
| <b>Neutrophiles</b> | in % of leukocytes for $T_0/ T_1/\Delta$ ; data imputation of 14% |
| <b>Lymphocytes</b>  | in % of leukocytes for $T_0/ T_1/\Delta$ ; data imputation of 13% |
| <b>Monocytes</b>    | in % of leukocytes for $T_0/ T_1/\Delta$ ; data imputation of 14% |

|                      |  |
|----------------------|--|
| <b>Thrombocytes</b>  | in G/l for $T_0/ T_1/\Delta$ ; data imputation of 1%   |
| <b>ALT</b>           | in U/l for $T_0/ T_1/\Delta$ ; data imputation of 5%, Alanine Aminotransferase                               |
| <b>Creatinine</b>    | in mg/dl for $T_0/ T_1/\Delta$ ; data imputation of 1%   |
| <b>CK-MB</b>         | in U/l for $T_0/ T_1/\Delta$ ; data imputation of 30%, CK-MB = Creatine Kinase Myocardial Band               |
| <b>LDH</b>           | in U/l for $T_0/ T_1/\Delta$ ; data imputation of 10%, LDH = Lactate Dehydrogenase                           |
| <b>Troponin T</b>    | in ng/ml for $T_0/ T_1/\Delta$ ; data imputation of 27%  |
| <b>CRP</b>           | in mg/dl for $T_0/ T_1/\Delta$ ; data imputation of 1%   |
| <b>IL-6</b>          | in pg/ml for $T_0/ T_1/\Delta$ ; data imputation of 23%, IL-6 = Interleukin-6                                |
| <b>Procalcitonin</b> | in ng/ml for $T_0/ T_1/\Delta$ ; data imputation of 6%   |
| <b>APTT</b>          | in seconds for $T_0/ T_1/\Delta$ ; data imputation of 3% , Activated Partial Thromboplastin Time             |
| <b>Fibrinogen</b>    | in mg/dl for $T_0/ T_1/\Delta$ ; data imputation of 34%  |
| <b>INR</b>           | no unit for $T_0/ T_1/\Delta$ ; data imputation of 2%, INR = Prothrombin Time International Normalized Ratio |
| <b>D-dimer</b>       | in $\mu$ g/ml for $T_0/ T_1/\Delta$ ; data imputation of 13%   |

#### 1.4 Image-derived features

We computed the volume of the following five CT labels at two times, namely  $T_0$  (initial CT) and  $T_1$  (follow up CT) and computed their  $\Delta$  by subtracting the first volume from the follow up volume.


|                         |   |
|-------------------------|---|
| <b>Lung</b>             | in ml for $T_0/ T_1/\Delta$ ; in % of initial lung volume for $\Delta$  |
| <b>Healthy</b>          | in ml for $T_0/ T_1/\Delta$ ; in % of initial lung volume for $T_0/\Delta$ ; in % of follow up lung volume for $T_1$ ]                            |
| <b>GGO</b>              | in ml for $T_0/ T_1/\Delta$ ; in % of initial lung volume for $T_0/\Delta$ ; in % of follow up lung volume for $T_1$ ], GGO = ground glas opacity |
| <b>Consolidation</b>    | in ml for $T_0/ T_1/\Delta$ ; in % of initial lung volume for $T_0/\Delta$ ; in % of follow up lung volume for $T_1$ ]                            |
| <b>Pleural effusion</b> | in ml for $T_0/ T_1/\Delta$ ; in % of initial pleural effusion volume for $\Delta$  |

After registration we detected the status transition of the lung parenchyma from the the initial CT ( $T_0$ ) to the follow up CT ( $T_1$ ) voxel-wise. The status options are consolidation (cons), ggo (ggo) and healthy lung tissue (healthy). The different status transition options (see below) are named after the following system: “(voxel status at  $T_0$ ) 2 (voxel status at  $T_1$ )” The number 2 is just seen as synonym of the word “(in)to”, like one status turns “into” another status. Summing up voxels with the same status transition we calculated the volume for each lung. As “common lung” we defined the intersection of the two label maps at  $T_0$  and  $T_1$  after their registration.

|                        |                              |
|------------------------|------------------------------|
| <b>Healthy2Healthy</b> | in ml; in % of “common lung” |
| <b>Healthy2GGO</b>     | in ml; in % of “common lung” |

|                       |  |
|-----------------------|--|
| <b>Healthy2Cons</b>   | in ml; in % of “common lung”   |
| <b>GGO2GGO</b>        | in ml; in % of “common lung”   |
| <b>GGO2Cons</b>       | in ml; in % of “common lung”   |
| <b>GGO2Healthy</b>    | in ml; in % of “common lung”   |
| <b>Cons2Cons</b>      | in ml; in % of “common lung”   |
| <b>Cons2GGO</b>       | in ml; in % of “common lung”   |
| <b>Cons2Healthy</b>   | in ml; in % of “common lung”   |
| <b>Lung improving</b> | in % of “common lung”; this feature is defined as the sum of status “Cons2GGO”, “Cons2Healthy” and “GGO2Healthy” |
| <b>Lung worsening</b> | in % of “common lung”; this feature is defined as the sum of status “Healthy2GGO”, “Healthy2Cons” and “GGO2Cons” |

## 2 Correlation of longitudinal imaging and dynamic inflammatory data



**Fig. 1.** Correlation (and its significance) between dynamic change of image-features and dynamic change of inflammatory parameters; lung improving/worsening and state transition in percentage of common lung, lung/cons/ggo/healthy  $\Delta$  in percentage of initial lung volume and plef  $\Delta$  in ml (left to right: both waves, 1st wave, 2nd wave).